Quanterix CORP 10-Q quarterly reports

Quanterix Corporation's Q2 2026 Form 10-Q reveals revenue growth driven by acquisitions, but also a substantial goodwill impairment charge and a revised cash flow breakeven timeline.

Quanterix Corporation reported a 20% increase in total revenues for the first quarter of 2026, driven by the Akoya Biosciences acquisition, while also detailing strategic adjustments and a significant impairment charge.

Quanterix reported a significantly wider net loss in Q3 2025, driven by acquisition costs, restructuring, and macroeconomic pressures, despite revenue growth from the Akoya Biosciences acquisition.

Quanterix Corporation reported a significant increase in net loss for Q2 2025, driven by declining revenues and a $6.4 million goodwill impairment charge, while strategically acquiring Akoya Biosciences and implementing cost reductions.

Quanterix Corporation announces its Q1 2025 financial results, a restructuring plan to reduce operating costs, and an update on its agreement to acquire Akoya Biosciences.

Quanterix Corporation released its third quarter 2024 financial results, which included a restatement of prior period financials and updates on strategic initiatives.

Quanterix Corporation has filed an amended quarterly report to restate its financials due to an error in inventory valuation and other unrelated adjustments.

Quanterix Corporation has filed an amended quarterly report to restate its financial statements for Q1 2024 and prior periods due to an error in inventory valuation and other unrelated adjustments.

Quanterix saw a modest increase in total revenue for Q2 2024, driven by consumables and service growth, but experienced a decline in instrument sales.

Quanterix saw a 13% increase in total revenue in Q1 2024, driven by strong growth in service revenue, while instrument sales experienced a decline.